First UK patients enroll in Phase 3 clinical trials of LMTX™ for Alzheimer’s Disease
Aberdeen, United Kingdom, 22 May 2013 – Coinciding with Dementia Awareness Week in the UK, TauRx Therapeutics Ltd announced that the first of more than 100 UK patients have enrolled in the global Phase 3 clinical trials of LMTX™ for mild to moderate Alzheimer’s disease.
“The initiation of our clinical studies in the UK marks an important step forward in our quest to find a disease-modifying agent that can help slow or halt the progression of Alzheimer’s disease,” said Prof. Claude Wischik, Executive Chairman and Co-Founder of TauRx Therapeutics. “Unlike cancer, for Alzheimer’s there are no ‘Alzheimer’s survivors’, so a medicine that can keep people functioning and at home longer is essential.”
The Phase 3 trials of the tau aggregation inhibitor target ‘tau tangles’ in the brain, and could provide the first definitive data on a tau-based treatment that dissolves the tangles and slows or halts Alzheimer’s disease.
Prof. Wischik added, “It is hoped that this study will shed new light on our understanding of how tau tangles form, their role in dementia, and ultimately how to stop them from spreading in the brain. LMTX™ could also provide a basis for preventive treatment of Alzheimer’s before any symptoms appear.”
The two large, Phase 3 studies will involve over 1,500 patients in more than 20 countries, with about 16 medical centres participating in the UK. These studies culminate three decades of research by Professor Claude Wischik and colleagues at TauRx Therapeutics, a spin-out company from the University of Aberdeen, Scotland established 11 years ago. According to the UK’s Alzheimer’s Society, there are currently 800,000 people in the UK living with dementia and this is expected to grow to over a million people by 2021. Currently no treatments are available to stop or reverse this devastating disease, which is now one of the leading causes of death in the UK.
About TauRx Therapeutics:
TauRx Therapeutics Ltd was established in Singapore in 2002 with the aim of developing new treatments and diagnostics for a range of neurodegenerative diseases. The company’s tau aggregation inhibitor, LMTX™, is currently in global Phase 3 clinical trials for Alzheimer’s and Frontotemporal Dementia (FTD). LMTX™ targets aggregates of abnormal fibres of tau protein that form inside nerve cells in the brain, giving rise to tangles. TauRx’s primary research facilities are in Aberdeen, Scotland.
For press enquiries please contact:
Sylvie Berrebi +44 (0)7795 197271
Got an innovation you need bringing to life?
We’d love to hear from you! Head to our contact page to start a conversation.